PierianDx will be highlighting germline features of its genomics technology platform at the American College of Medical Genetics and Genomics (ACMG) annual meeting April 2-6 in Seattle, Washington.
Representatives from PierianDx will be on hand in Booth 523 to answer your questions about Clinical Genomics WorkSpace, our integrated workspace for genomic analytics, classification, interpretation and reporting.
CGW germline testing features include phenotype-based prioritization of variants and rapid classification of variants following ACMG guidelines.
PierianDx complements its germline technology with a range of support services. The company’s interpretation services involves clinical and scientific teams leveraging the PierianDx patented knowledgebase to provide highly scalable and reliable clinical interpretations for inherited diseases. Interpretations by PierianDx variant scientists and medical directors are combined with machine learning within the knowledgebase comprised of million of biomedical findings to produce the most clinically actionable insights available for customers.